119 related articles for article (PubMed ID: 37330023)
21. lncRNA A1BG-AS1 suppresses proliferation and invasion of hepatocellular carcinoma cells by targeting miR-216a-5p.
Bai J; Yao B; Wang L; Sun L; Chen T; Liu R; Yin G; Xu Q; Yang W
J Cell Biochem; 2019 Jun; 120(6):10310-10322. PubMed ID: 30556161
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of lncRNA SBF2-AS1 inhibits hepatocellular carcinoma proliferation and migration by regulating the miR-361-5p/TGF-β1 signaling pathway.
Wu YH; Yu B; Chen WX; Ai X; Zhang W; Dong W; Shao YJ
Aging (Albany NY); 2021 Aug; 13(15):19260-19271. PubMed ID: 34341185
[TBL] [Abstract][Full Text] [Related]
23. Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway.
Song W; Zhang J; Xia Q; Sun M
Cell Cycle; 2019 Nov; 18(22):3177-3188. PubMed ID: 31564201
[No Abstract] [Full Text] [Related]
24. LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis.
Huang Y; Xiang B; Liu Y; Wang Y; Kan H
Cancer Lett; 2018 Nov; 437():56-66. PubMed ID: 30165194
[TBL] [Abstract][Full Text] [Related]
25. LncRNA NUTM2A-AS1 aggravates the progression of hepatocellular carcinoma by activating the miR-186-5p/KLF7-mediated Wnt/beta-catenin pathway.
Long J; Liu L; Yang X; Zhou X; Lu X; Qin L
Hum Cell; 2023 Jan; 36(1):312-328. PubMed ID: 36242728
[TBL] [Abstract][Full Text] [Related]
26. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.
Lei T; Zhu X; Zhu K; Jia F; Li S
Cancer Biol Ther; 2019; 20(7):1007-1016. PubMed ID: 30929558
[TBL] [Abstract][Full Text] [Related]
27. lncRNA Ftx promotes aerobic glycolysis and tumor progression through the PPARγ pathway in hepatocellular carcinoma.
Li X; Zhao Q; Qi J; Wang W; Zhang D; Li Z; Qin C
Int J Oncol; 2018 Aug; 53(2):551-566. PubMed ID: 29845188
[TBL] [Abstract][Full Text] [Related]
28. Long noncoding RNA ZFPM2-AS1 regulates ITGB1 by miR-1226-3p to promote cell proliferation and invasion in hepatocellular carcinoma.
Liu W; Zhang GQ; Zhu DY; Wang LJ; Li GT; Xu JG; Jin XL; Zhu YM; Yang XY
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7612-7620. PubMed ID: 32744687
[TBL] [Abstract][Full Text] [Related]
29. Long non-coding RNA F11-AS1 inhibits HBV-related hepatocellular carcinoma progression by regulating NR1I3 via binding to microRNA-211-5p.
Deng Y; Wei Z; Huang M; Xu G; Wei W; Peng B; Nong S; Qin H
J Cell Mol Med; 2020 Jan; 24(2):1848-1865. PubMed ID: 31880390
[TBL] [Abstract][Full Text] [Related]
30. LncRNA ZEB1-AS1 regulates hepatocellular carcinoma progression by targeting miR-23c.
Xue S; Lu F; Sun C; Zhao J; Zhen H; Li X
World J Surg Oncol; 2021 Apr; 19(1):121. PubMed ID: 33865414
[TBL] [Abstract][Full Text] [Related]
31. LncRNA SNAI3-AS1 promotes PEG10-mediated proliferation and metastasis via decoying of miR-27a-3p and miR-34a-5p in hepatocellular carcinoma.
Li Y; Guo D; Lu G; Mohiuddin Chowdhury ATM; Zhang D; Ren M; Chen Y; Wang R; He S
Cell Death Dis; 2020 Aug; 11(8):685. PubMed ID: 32826862
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of
Liu Z; Dang C; Xing E; Zhao M; Shi L; Sun J
DNA Cell Biol; 2019 Nov; 38(11):1366-1373. PubMed ID: 31633393
[TBL] [Abstract][Full Text] [Related]
33. The HNF1α-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1.
Ding CH; Yin C; Chen SJ; Wen LZ; Ding K; Lei SJ; Liu JP; Wang J; Chen KX; Jiang HL; Zhang X; Luo C; Xie WF
Mol Cancer; 2018 Feb; 17(1):63. PubMed ID: 29466992
[TBL] [Abstract][Full Text] [Related]
34. LncRNA FLVCR1-AS1 acts as miR-513c sponge to modulate cancer cell proliferation, migration, and invasion in hepatocellular carcinoma.
Zhang K; Zhao Z; Yu J; Chen W; Xu Q; Chen L
J Cell Biochem; 2018 Jul; 119(7):6045-6056. PubMed ID: 29574975
[TBL] [Abstract][Full Text] [Related]
35. Long non-coding RNA AGAP2-AS1, functioning as a competitive endogenous RNA, upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma.
Liu Z; Wang Y; Wang L; Yao B; Sun L; Liu R; Chen T; Niu Y; Tu K; Liu Q
J Exp Clin Cancer Res; 2019 May; 38(1):194. PubMed ID: 31088485
[TBL] [Abstract][Full Text] [Related]
36. Long noncoding RNA HAND2-AS1 reduced the viability of hepatocellular carcinoma via targeting microRNA-300/SOCS5 axis.
Bi HQ; Li ZH; Zhang H
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):567-574. PubMed ID: 32224127
[TBL] [Abstract][Full Text] [Related]
37. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
Gao J; Dai C; Yu X; Yin XB; Zhou F
Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
[TBL] [Abstract][Full Text] [Related]
38. LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells.
Sun J; Zheng X; Wang B; Cai Y; Zheng L; Hu L; Lu X; Xie S; Zhang X; Liu H; Ye L
Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(2):261-270. PubMed ID: 35130616
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis B virus X protein related lncRNA WEE2-AS1 promotes hepatocellular carcinoma proliferation and invasion.
Hu Z; Huang P; Yan Y; Zhou Z; Wang J; Wu G
Biochem Biophys Res Commun; 2019 Jan; 508(1):79-86. PubMed ID: 30471857
[TBL] [Abstract][Full Text] [Related]
40. N
Liu J; Zhang N; Zeng J; Wang T; Shen Y; Ma C; Yang M
Clin Transl Med; 2022 Nov; 12(11):e1107. PubMed ID: 36354136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
